The scientists have confirmed that simultaneous treatment with HDM2 antagonists and BCL-2 inhibitors results in greater induction of apoptosis and reduction of cell viability of AML cells, multiple myeloma, and blast crisis myeloid leukemia cells. Here, MDM2 is linked to acute myeloid leukemia.